[Clinical trials of a new preparation in chronic bronchopneumopathies].
The new preparation Broncaspin (guacetisal) has been experimented in the form of 1.2 g suppositories and 5% suspension, in 40 patients suffering from chronic bronchopneumopathy at acute phase. The drug exerted a marked therapeutic action in objective and subjective symptomatology in 87.5% of cases. The action was manifold in relation to the typical expectorant fluidifying, bronchiole disobstructing and anti-inflammatory characteristics of the drug. Tolerance was always excellent.
D000328:Adult; D000368:Aged; D001241:Aspirin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy; D001991:Bronchitis / Q000188:drug therapy*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003371:Cough / Q000188:drug therapy; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011656:Pulmonary Emphysema / Q000188:drug therapy; D012119:Respiration / Q000187:drug effects; D012829:Silicosis / Q000188:drug therapy; D014136:Tracheitis / Q000188:drug therapy
D001241:Aspirin; C023557:guacetisal
Sperimentazione clinica di un nuovo preparato nelle broncopneumopatie croniche.